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The prevalence of diabetes is rising globally and, as a result, its associated complications are also rising. Painful diabetic neuropathy
(PDN) is a well-known complication of diabetes and themost common cause of all neuropathic pain. About one-third of all diabetes
patients suffer fromPDN. It has a huge effect on a person’s daily life, both physically andmentally. Despite huge advances in diabetes
and neurology, the exact mechanism of pain causation in PDN is still not clear.The origin of pain could be in the peripheral nerves
of the central nervous system. In this review, we discuss various possible mechanisms of the pathogenesis of pain in PDN. We
discuss the role of hyperglycaemia in altering the physiology of peripheral nerves. We also describe central mechanisms of pain.
1. Introduction
Diabetes affects 382 million people wordlwide and its preva-
lence is expected to increase to 592 million by the year
2035 [1]. Diabetic neuropathy, a well-known, long-term
complication of diabetes, can affect almost half of the diabetic
population [2] and is associated with higher morbidity and
mortality [3]. Diabetic neuropathy encompasses a variety of
clinical or subclinical presentations. Painful diabetic neu-
ropathy (PDN) is a common type of diabetic neuropathy
and the most common cause of neuropathic pain [4]. The
reported prevalence of PDN varied from 11% in Rochester,
Minnesota, USA [5], to 53.7% in the Middle East [6]. One
UK study published in 2011 reported that the prevalence of
PDNwas 21.5% in type 2 diabetes patients and 13.4% in type 1
diabetes patients, resulting in an overall prevalence of 21% [7].
In the large, prospective EURODIAB study in 16 European
countries, almost one-quarter of type 1 patients developed
new onset painful diabetic neuropathy over a seven-year
period [8]. A prospective study in Finland followed newly
diagnosed diabetes patients between the ages of 45 and 64
years for 10 years. It found a 6% prevalence at the time
of diagnosis of diabetes and a 26.4% prevalence at the 10-
year follow-up [9]. In a large UK-based community diabetic
population, Abbot et al. [7] observed that increasing age was
directly related to painful symptoms of neuropathy. Most
studies found no significant difference in gender; however,
Abbot et al. [7] reported a slightly higher prevalence of
painful symptoms of neuropathy in females (38%) than
males (31%). The same study also found a higher prevalence
of painful symptoms in South Asians (38%) compared to
Europeans (32%).
Painful diabetic neuropathy (PDN) symptoms exhibit a
symmetrical “stocking and gloves” distribution and are often
associated with nocturnal exacerbation. It can be presented
from a mild pins and needle sensation to stabbing, burning,
unremitting, or even unpleasant electric shock sensation.
There can be allodynia in the form of cutaneous hypersen-
sitivity leading to acute distress on contact with an external
stimulus, such as clothing [10]. The pain is often worse
at night and often disturbs sleep, causing tiredness during
the day. Some patients present with distressing allodynia
and severe pain in the legs. This may be so painful that it
prevents them from performing their daily activities, thereby
impacting their employment and social life. The constant,
unremitting pain and withdrawal from social life often result
in depression [11]. In extreme cases, patients lose their
appetite and experience significant weight loss, which is
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reported in the literature as “diabetic neuropathic cachexia”
[10].
2. Physiology of Pain
Pain is the body’s perception of actual or potential damage to
the nerve or tissue by noxious stimuli. The sensory afferent
nerves carry sensations from the skin, joints, and viscera
via large and small fibres. Large fibres, such as A-alpha, are
responsible for limb proprioception and A-beta fibres carry
sensations of limb proprioception, pressure, and vibration.
Large A-delta myelinated fibres and small C unmyelinated
fibres are mainly responsible for carrying nociceptive sen-
sations. Superficial pain is often a sharp or pricking sen-
sation and is transmitted by A-delta fibres. A deep-seated,
burning, itching, aching type of pain is often accompa-
nied with hyperalgesia and allodynia and is transmitted via
slow, unmyelinated C fibres. Tissue damage results in the
release of inflammatory chemicals, such as prostaglandins,
bradykinins, and histamines, at the site of inflammation,
which triggers the depolarization of nociceptors, thereby
generating an action potential.The action potential transmits
the nociceptive sensation, via the dorsal root ganglion (DRG),
to the dorsal horn of the spinal cord.The release of glutamate
and substance P results in the relay of nociceptive sensations
to the spinothalamic tract, thalamus, and, subsequently, the
cortex, where pain is interpreted and perceived [12].
Nociceptive pain is the normal response to noxious insult
or injury of tissues such as skin, muscles, visceral organs, and
joints. Nociceptive pain usually subsides upon the healing of
the tissue injury. On the other hand, neuropathic pain arises
as a direct consequence of a lesion or disease affecting the
somatosensory system without any noxious stimuli. Neuro-
pathic pain is caused by damage or pathological change and
is characterised by the activation of abnormal pathways of
pain at the peripheral nerves and posterior roots (peripheral
neuropathic pain) or spinal cord and brain (central pain) [13].
Neuropathic pain manifestation can be focal, multifocal, or
generalized depending on the involvement of peripheral or
central origin and cause of the disease. A few examples of
neuropathic pain are listed in Table 1.
3. Neuropathic Pain Generation Pathogenesis
Theorigin of pain in PDN is not fully understood.The abnor-
malities in the peripheral or central nervous system could
be related to hyperglycaemia, as this is the key metabolic
abnormality of diabetes.There aremany other conditions that
produce pain similar to that of PDNand theymay also aid our
understanding of the pathophysiology of PDN.
3.1. Ectopic Electrical Impulses. Chronic hyperglycemic dam-
age to the nerves can cause regeneration of nerve sprouts,
called neuromas, at the stump. The sprouting of the new
nerves in all directions causes collateral damage of otherwise
undamaged nerves and expands the sensitized area [14].
Hyperexcitability in the neuroma generates ectopic impulses
that affect neighbouring intact afferents and the cell bodies
Table 1: Examples of neuropathic pain.






















of the DRG. It leads to spontaneous, exaggerated, abnormal
hyperexcited responses, along with increased sensitivity to
a given stimulus [15]. This phenomenon is called peripheral
sensitization. Electrical impulses from the axon of small fibres
at the dorsal horn of the spinal cord are increased and, hence,
it alters the “gate” (described below) and causes the release of
substance P and glutamate.This causes a relay of the impulses
to the ascending track, which is perceived as pain [16].
3.2. Change in Glucose Flux and Pain. Treatment of induced
acute neuropathy due to rapid glycemic control in the first
month of the initiation of insulin or oral hypoglycemic
agents has been reported in the literature as “insulin neuritis.”
In 1992, Boulton [17] first described the observation that
acute painful neuropathy might follow a sudden change in
glycaemia control, suggesting that blood glucose flux could
precipitate pain. This observation was experimentally tested
in rats by Kihara et al. in 1994 [18]. In their study, they infused
insulin under nonhypoglycemic conditions and evaluated its
effect on endoneurial oxygen tension, nerve blood flow, and
the oxyhaemoglobin dissociation curve of peripheral nerves
in normal and diabetic rats. Their results showed that insulin
administration caused a reduction in nerve nutritive blood
flow and an increase in arteriovenous shunt flow. When the
arteriovenous shunts were obliterated by the infusion of 5-
hydroxytryptamine, endoneurial oxygen reverted to normal.
Sudden changes in glycaemia may induce relative hypoxia in
nerve fibres, which contributes to the generation of impulses,
thereby indicating that it is the combination of structural and
functional changes in peripheral nerves that cause the pain.
In 1996, Tesfaye et al. [19] observed neurovascular
changes in vivo in five human diabetic patients with insulin
neuritis. These patients presented with severe sensory symp-
toms but clinical examination and electrophysiological tests
were normal, except in one subject who had severe autonomic
neuropathy. On sural nerve exposure in vivo, epineural
blood vessels showed severe structural abnormalities resem-
bling the retinopathy changes normally seen in the retina,









Figure 1: Arteriolar attenuation (A), tortuosity (B), arteriovenous
shunting (C), and proliferation of newly formed vessels (D) of the
vasa nervosum seen in the sural nerve of a patient with insulin
neuritis (photo courtesy of Tesfaye).
including arteriolar attenuation, tortuosity, arteriovenous
shunting, and the proliferation of newly formed vessels.They
hypothesized that the structural abnormalities in epineural
blood vessels, together with the formation of new vessels,
caused a steal effect and, hence, resulted in hypoxia and
neuropathic pain. It can now be postulated that a sudden
change in glycemic control can cause flux effects that result
in structural and functional changes in the epineural blood
vessels of nerves, which, in turn, can lead to neuropathic
pain or “insulin neuritis” [17, 19] (Figure 1). Symptoms can be
mild and often go unreported but may present with severe,
excruciating neuropathic pain. Symptoms usually last up to
six months and respond to treatment that is usually needed
for up to six months [10].
3.3. Role of the Dorsal Root Ganglion in Neuropathic Pain.
The expression of voltage-gated sodium and calcium chan-
nels and voltage-independent potassium channels in the
DRG has a significant role in the generation of nociceptive
sensation and peripheral sensitization that leads to central
sensitization. Hyperexcited ectopic impulses are generated
by the expression of various voltage-gated sodium channels,
such as Nav1.3, Nav1.7, and Nav1.8 [20]. The voltage-gated
sodium channel Nav1.3 probably plays a key role in the
development of neuropathic pain [21]. Amir et al. described
after nerve injury, in theDRG, the fact that there is a sustained
phasic discharge that results in repeated firing [22]. The
voltage-dependent sodium channel alternates with a voltage-
independent potassium leak to oscillate membrane poten-
tials. When these oscillations reach the threshold amplitude,
they result in the generation of ectopic impulses and, hence,
lead to sustained peripheral sensitization [23]. In addition to
the voltage-gated sodium channels, the expression of voltage-
gated calcium channels was also found in neuropathic pain
[24]; specifically subtype Cav 3.2 is highly expressed in
DRG neurons and showed strong correlation with allodynia
[25]. Calcium entry through voltage-gated calcium channels
causes the release of substance P and glutamate, which results
in the modulation of pain at the dorsal horn [26]. The
upregulation of transient receptor potential expression is also
found to be associated with neuropathic pain. Studies found
a direct relationship between TRPV1 (transient receptor
potential vanilloid 1) and neuropathic pain. A few animal
studies suggest that hyperalgesia does not develop in TRPV1-
deficient mice and TRPV1 antagonists reduce pain behaviour
in mice [27, 28].
3.4. Methylglyoxal and Pain. Methylglyoxal (MG) is a reac-
tive intracellular by-product of several metabolic pathways.
However, the most important source of MG is glycolysis and
hyperglycaemia [29]. Studies found that PDN patients had
significantly higher concentration of plasma MG (>600 nM)
compared to healthy control or diabetes patients without pain
[30, 31]. MG depolarizes the sensory neuron by activating
TRPV1 in the DRG [32] and also induces posttranslational
modification of the voltage-gated sodium channel Nav1.8
[30]. These changes are associated with increased electrical
excitability and facilitate firing of nociceptive neurons.
3.5. Sympathetic Modulation of Pain. Nociceptive A-delta
and C fibres are normally not directly connected to
sympathetic nervous system. Several experiments using
𝛼-adrenoreceptor agonists found that it did not activate
sympathetic neurons at nociceptor fibres under normal con-
ditions [33, 34]. It is widely accepted that the sympathetic
nervous system does not activate the sensory nervous system
under normal conditions.
Neuropathy causes hypersensitivity in nerves as a result
of an abnormal epinephrine-mediated transmission from
one axon to another. This unusual connection is called
ephaptic transmission or cross-talk [35]. It was also noted
that damaged nerves in the periphery also cause basket
formation, called sympathetic sprouting in the DRG, which
results in the release of noradrenaline [36]. Both sympathetic
sprouting and ephaptic transmission release adrenaline and
cause sympathetic-sensory coupling.This leads to an increase
in ectopic and spontaneous firing.This unusual connection is
called sympathetically maintained pain.
Several studies proved this hypothesis and showed dra-
matic improvement in pain relief after sympathetic block-
age [37], sympathectomy [38], or temporary blockage with
𝛼-adrenergic antagonists with intravenous phentolamine
[39].
3.6. Gate Control Theory. In 1965, Melzak and Wall [40]
described, for the first time, the fact that nervous connections
from the peripheral to central nervous system and to the
brain are not a seamless transmission of information. They
described the gate mechanism at the dorsal horn of the spinal
cord, which inhibits or facilitates the flow of afferent impulses
fromperipheral nerves to the spinal cord before it evokes pain
perception.The activity at the gate is primarily dependent on
the transmission of impulses along small or large nerve fibres.
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Small nerve fibres, unmyelinated C fibres, and myelinated A-
delta fibres tend to open the gate and large A-beta fibres tend
to close the gate. Opening and closing of the gate depend on
the number of input impulses.Thus, if nociceptive input from
C- and A-delta fibres exceeds A-beta fibre input, then the gate
is open and nociceptive impulses ascend to the spinal cord.
On the other hand, if A-beta fibre input (touch, vibration,
and pressure) exceeds that of C- and A-delta fibre input
(pain), then the gate is closed; nociceptive impulses only pass
through when the gate is open. The classic example of this
phenomenon is the rubbing of an injured site immediately
after suffering from trauma, which results in gate closure.
3.7. Central Sensitization. Central sensitization was first
described by Woolf in 1983. Nonnoxious stimuli transmitted
from the periphery with A-beta fibres (touch) were perceived
as painful by patients with allodynia [41]. A-delta fibres and
C fibres are innervated in laminae I-II and A-delta fibres also
are innervated in laminaV of the dorsal horn.Themajority of
spinal cord neurons that express the substance P receptor are
located in lamina I or have their cell bodies in laminae III-IV
but extend their dendrites to lamina I. The pain mediation
of noxious stimuli occurs by releasing substance P, mainly
in lamina I of the dorsal horn. A-beta fibres are innervated
deep in laminae III to V and are responsible for touch
mediation [42–44]. Peripheral sensitization and sustained
hyperexcited impulses at the dorsal horn cause an increase in
responsiveness to noxious and nonnoxious stimulation. This
was believed to be due to the structural plasticity of sprouting
of A-beta fibres, which leads to “rewiring” of the dorsal horn
laminae in the central nervous system (CNS) [44]. As a result,
the CNS pathway, which is responsible for transmitting only
nonnoxious stimuli (touch), was replaced by sprouting A-
beta fibres that transmit nonnoxious impulses and release
substance P in the dorsal horn, thereby mediating allodynia
[45]. This hypothesis was mainly based on experiments
that showed that the uptake of the cholera toxin B (CTB)
subunit, which is a selective tracer for large myelinated A-
fibres, terminated in lamina II [46]. The selectivity of this
toxin after peripheral nerve injury is somewhat controversial.
Experiments demonstrated that uptake of the CTB tracer
was not selective, that CTB was found in axons of all types,
including A-delta fibres and C fibres, and that the CTB
tracer incorporated in C fibres that terminated in lamina II
[47]. This contradicts the hypothesis of structural plasticity
and A-beta fibres sprouting in lamina II. However, studies
with immunostaining and electrophysiological recordings
have clearly established that peripheral nerve injury causes
large myelinated fibres to begin to drive nociceptive neu-
rons in superficial lamina [48, 49]. The persistent incoming
nerve impulses lead to activation of N-methyl-D-aspartate
(NMDA) receptors on postsynaptic membranes in the dorsal
horn of the spinal cord. This leads to the release and binding
of glutamate (an excitatory neurotransmitter), which causes
an influx of sodium and calcium and an efflux of potassium.
This generates a larger postsynaptic action potential and
augments the perception of normal stimuli, thereby resulting
in allodynia [50].
3.8. Central Inhibition. Impulses from the brainstem nuclei
descend to the spinal cord and influence the transmission
of pain signals at the dorsal horn. The periaqueductal grey
matter (PAG), locus coeruleus, the nucleus raphe magnus,
and several bulbar nuclei of reticular formation give rise to
descending modulatory pathways. These pathways dampen
or enhance the pain signal. The projections from the nucleus
raphe magnus to the spinal cord are the major source of
serotonin in the spinal cord. Exogenous opioids imitate the
endogenous opioids and induce analgesia by acting upon the
PAG, reticular formation, and the spinal dorsal horn [12].
The antidepressant serotonin and norepinephrine reuptake
inhibitors (SNRIs) [51] and opioids [52] have been found to
be beneficial in the treatment of neuropathic pain as these
medications increase the availability of these neurotrans-
mitters and, hence, increase inhibition at the spinal cord.
Psychological factors, such as fear and anxiety, can influence
the inhibitory mechanism through the modulatory system.
Cognitive behavioural therapies are thought to be beneficial
in modulating the pain by reducing the fear and anxiety [53].
3.9. Thalamic Abnormalities. The nociceptive hyperexcited
impulse generated within primary afferent nerves is modu-
lated and amplified not only at the DRG-spinal cord level but
also at the thalamic ventral posterolateral (VPL) level, before
being relayed to the cerebral cortex. This was experimentally
proved in streptozosin rat model with PDN. The experiment
demonstrated hyperexcitability in thalamic VPL neurons,
with increased responses to phasic brush, press, and pinch
stimuli applied to peripheral receptive fields. VPL neurons
from diabetic rats also displayed enhanced spontaneous
activity, independent of ascending afferent impulses, and
enlarged receptive fields [54]. Selvarajah et al. [55] investi-
gated this further in humans using a magnetic resonance
(MR) perfusion scan in patients with PDN. This study
demonstrated increased thalamic vascularity and sluggish
blood flow. Similar vascular perfusion findings were also
observed at the sural nerve in patients with PDN [56]. It was
suggested that increased perfusion at thalamus VPL neurons
in PDN patients causes an increase in neuronal activity and,
hence, further modulates pain and central sensitization.
3.10. Chronic Neuropathic Pain and Plasticity of Brain. Neu-
roplasticity or plasticity of the brain is the term used to
describe the adaptive change in structure, chemical bal-
ance, and function of the brain in response to changes
within the body or in the external environment. In response
to chronic neuropathic pain, neuroplasticity is associated
with somatosensory cortex remodelling, reorganization, and
hyperexcitability in the absence of external stimuli. A study of
patients with chronic neuropathic and nonneuropathic pain
using functional and anatomicalmagnetic resonance imaging
found cortical reorganization and changes in somatosensory
cortex activity only in the neuropathic pain group [57].
Provoked pain and spontaneous stimuli may reverse the
remodelling and reorganization at the somatosensory cortex.
Studies have shown a beneficial effect of pain relief with
transcranial magnetic stimulation (TMS) and transcranial
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direct current stimulation (tDCS), which suggests a reversal
of plasticity [58, 59].
4. Conclusion
In summary, the exact mechanism of pain in PDN is far
from being clear. The source of pain could be anywhere in
the pathway from the damaged nerves to the somatosensory
cortex or it could be due to a combination of pathologies.
PDN is a distressing condition and, as a result, adversely
affects a patient’s quality of life, both physically and mentally.
Despite significant advances in therapeutics, the treatment
of chronic symptoms of pain in PDN is still suboptimal
and challenging for clinicians [11, 60]. This may be due to
a poor understanding of the pathogenesis of PDN. There is
an increasing body of evidence that suggests that the central
nervous system is primarily responsible for maintaining
painful symptoms. In recent years, there have been significant
advances in the neuroimaging of pain. Further research is
needed to have a better understanding of the disease process
of PDN, which will help to tackle this enormous challenge.
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